Nielsen releases Zyrtec OTC panel results
NEW YORK NielsenHealth, a Nielsen Company service focused on healthcare, released findings Thursday that found that 62 percent of Zyrtec OTC buyers took an allergy prescription in the last 12 months, and of those buyers, more than 53 percent claimed to be “very satisfied” with their Rx allergy medication at the time.
“This is an important finding,” stated Matt Dumas, managing director of NielsenHealth. “[It’s] a signal that OTC alternatives to allergy prescriptions may become the preference to both consumers and managed care providers in large part due to efficacy and price.”
The findings are from NielsenHealth’s newly launched Allergy Panel, one of 32 new NielsenHealth Ailment Panels being launched to provide manufacturers and retailers insights into consumer related attitudes and behaviors of patients with specific conditions.
Additional findings from the Allergy Panel found that 42 percent of Zyrtec OTC buyers who claim to experience spring time allergies have severe allergy symptoms. The research also found that 22 percent of the allergy sufferers in the panel treat their condition with Rx medication alone and 23 percent use concomitant Rx/OTC therapies. “This could have a significant impact on the holistic allergy market because it suggests that severe sufferers see OTC as an option whereas before this patient tended to migrate to Rx options only or concomitant Rx-OTC usage,” Dumas said. “It would not be surprising to see sufferers shift more to using OTC medications only over the next 6-12 months.”
The NielsenHealth Ailment Panels consist of 110,000 U.S. consumers identified as suffering from one or more ailments tracked by Nielsen, including allergy, gastro-intestinal ailments and conditions like diabetes, obesity and cardiovascular disease. Each Panel tracks panelists suffering a specific condition and their actual purchases, demographics, as well as critical patient facts relating to their specific conditions and treatment regimes.
NAD cites Green Willow Tree for overstatement of Thyodine effects
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday recommended that Green Willow Tree discontinue certain advertising claims for its Thyodine dietary supplement product, including that its product is a “safe, all-natural hormone,” and that “Thyodine helps to stimulate the thyroid gland to produce normal amounts of thyroid hormone again.”
In its defense, Green Will Tree maintained that Thyodine includes vitamins, amino acids, minerals, supplemental glandulars and other ingredients that have been generally accepted in the scientific and medical community as beneficial to, and supportive of, thyroid function.
However, NAD determined that the advertiser’s claims go beyond the simple message that Thyodine contains ingredients that have been shown to help support a healthy thyroid.
The company, in its advertiser’s statement, noted that it does not “fully agree with the conclusions.”
However, the company said that it would adjust advertising for Thyodine to “attempt to meet the recommendations submitted … by NAD.”
The claims were challenged by the Council for Responsible Nutrition, a trade association of dietary-supplement manufacturers.
Court upholds Perrigo claim to market generic Pepcid
WASHINGTON The U.S. Court of Appeals for the Federal Circuit last week affirmed a lower court’s decision in June 2007 that opened the door to Perrigo’s store brand version of McNeil Consumer’s Pepcid Complete.
The ruling enables Perrigo to begin shipping the heartburn reliever in the third quarter of this year, according to published reports.